Neuropediatrics 2017; 48(06): 482-483
DOI: 10.1055/s-0037-1606371
Videos and Images in Neuropediatrics
Georg Thieme Verlag KG Stuttgart · New York

Chorea Minor Associated with Anti-Neurochondrin Autoantibodies

Frank R. Rommel
1  Department of Child Neurology, Justus-Liebig University Gießen, Gießen, Germany
,
Ramona Miske
2  Institute of Experimental Immunology, Euroimmun AG, Lübeck, Germany
,
Winfried Stöcker
2  Institute of Experimental Immunology, Euroimmun AG, Lübeck, Germany
,
Borros Arneth
3  Department of Molecular Diagnostics, Institute of Laboratory Medicine and Pathobiochemistry, Justus-Liebig University Gießen, Gießen, Germany
,
Bernd A. Neubauer
1  Department of Child Neurology, Justus-Liebig University Gießen, Gießen, Germany
,
Andreas Hahn
1  Department of Child Neurology, Justus-Liebig University Gießen, Gießen, Germany
› Author Affiliations
Further Information

Publication History

11 July 2017

16 July 2017

Publication Date:
29 September 2017 (eFirst)

Introduction

Chorea minor is characterized by irregular, rapid, and chaotic movements, primarily affecting the hands, feet, and face. Autoimmune chorea minor, the most common form of acquired childhood chorea, is frequently triggered by antineuronal antibodies emerging after A β-hemolytic streptococcal infections,[1] [2] but other immunological abnormalities have also been reported.[3] Recently, antibodies against neurochondrin, an intracellular neuronal target antigen also expressed in striatum, were newly discovered and detected in three adults with cerebellar degeneration.[4] We report a 6-year-old girl who presented with choreatiform movements predominantly of the right arm and face ([Video 1], part I). Diagnostic workup revealed distinctly positive anti-neurochondrin antibodies in the patient's serum[4] ([Fig. 1A], [B]). Intravenous immunoglobulin (IVIG) treatment substantially improved the patient's clinical symptoms ([Video 1], part II), and anti-neurochondrin antibody titers became negative. After 12 weeks of cessation of IVIG treatment clinical symptoms and the autoantibodies reappeared ([Video 1], part III). IVIG treatment was restarted, and the girl's chorea improved again, while anti-neurochondrin autoantibodies ceased to exist ([Video 1], part IV). These observations suggest that anti-neurochondrin autoantibody determination may be meaningful in children with chorea minor.

Video 1 Part I: A 6-year-old girl with involuntary, jerky movements predominantly of the right arm, fidgetiness, and facial grimacing. Part II: Distinct reduction of symptoms during intravenous immunoglobulin (IVIG) treatment. Part III: Symptom relapse after cessation of IVIG therapy. Part IV: Improvement of clinical symptoms after restarting IVIG therapy. Online content including video sequences viewable at: www.thieme-connect.com/ejournals/html/doi/10.1055/s-0037-1606371.

Georg Thieme Verlag. Please enable Java Script to watch the video.
Zoom Image
Fig. 1 (A) Indirect immunofluorescence staining of recombinant neurochondrin transfected HEK293 cells incubated with 1:10 diluted patient serum and, in the second step, with fluorescein-labeled sheep antihuman IgG. (B) Antibody titers in relation to clinical symptoms.